[8-K] Bluejay Diagnostics, Inc. Reports Material Event

Rhea-AI Filing Summary

Bluejay Diagnostics entered into a private placement that closed on October 10, 2025, selling 175,000 shares of common stock and pre-funded warrants for up to 2,075,000 shares, together with Series F warrants for up to 4,500,000 shares. The combined price was $2.00 per share (or pre-funded warrant) plus accompanying Series F warrants to acquire two shares. The company received approximately $4.0 million in proceeds after fees.

Pre-funded warrants are immediately exercisable at $0.0001 per share and expire once exercised. Series F warrants are immediately exercisable at $1.75 per share and expire five and one-half years from issuance. The placement agent received warrants to purchase up to 180,000 shares, with an exercise price equal to 125% of the combined price per share and Series F warrants sold.

Bluejay agreed to register for resale the 175,000 shares and 6,755,000 warrant shares, file by October 24, 2025, and keep the registration effective until the registered shares may be sold under Rule 144. Issuances are restricted for 90 days after effectiveness, and certain variable-rate deals and splits are limited for one year. Warrant exercises are capped at 4.99% or 9.99% beneficial ownership, subject to notice-based adjustments.

Insights

Equity Capital Markets Analyst

$4.0M cash raised; sizable warrant overhang, resale to be registered.

Bluejay Diagnostics completed a private placement with net proceeds of $4.0 million, issuing common shares and multiple warrant classes. Pricing was a $2.00 combined unit with immediately exercisable pre-funded and Series F warrants; Series F carries a $1.75 exercise price and 5.5-year term.

The company agreed to register for resale 175,000 shares plus 6,755,000 shares underlying the warrants by October 24, 2025. Lock-up constraints limit new issuances for 90 days post-effectiveness, and variable-rate transactions and splits are restricted for one year, which may temper near-term dilution pathways.

Beneficial ownership limits of 4.99% or 9.99% per holder moderate instantaneous concentration from exercises. Actual market impact depends on holder exercise and sale decisions after effectiveness.

false 0001704287 0001704287 2025-10-09 2025-10-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 9, 2025

BLUEJAY DIAGNOSTICS, INC.

(Exact Name of Registrant as Specified in its Charter)

delaware		001-41031		47-3552922
(State or Other Jurisdiction of Incorporation or Organization)		(Commission File No.)		(I.R.S. Employer Identification No.)

360 Massachusetts Avenue, Suite 203

Acton, MA 01720

(Address of principal executive offices and zip code)

(844) 327-7078

(Registrant’s telephone number, including area code)

(Former name or former address, if changed from last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 Item 1.01. Entry into a Material Definitive Agreement.

On October 9, 2025, Bluejay Diagnostics, Inc. (the “Company”), in connection with a private placement of the Company’s securities, entered into with certain institutional, accredited investors (i) a securities purchase agreement, and (ii) a registration rights agreement. The private placement closed on October 10, 2025.

Pursuant to the purchase agreement, the Company offered and sold (i) an aggregate of 175,000 shares of the Company’s common stock (“common stock”) and pre-funded warrants to purchase up to 2,075,000 shares of common stock (“Pre-Funded Warrants”), and (ii) Series F warrants (“Series F Warrants”) to purchase up to 4,500,000 shares of common stock. The combined price of securities sold in the private placement was $2.00 per share of common stock (or pre-funded warrant in lieu thereof, in which case such price was reduced by $0.0001) and accompanying Series F Warrants to acquire two shares of common stock. The Pre-Funded Warrants are exercisable for shares of common stock at an exercise price of $0.0001 per share, are immediately exercisable and expire once exercised in full. The Series F Warrants are exercisable for shares of common stock at an exercise price of $1.75 per share, are immediately exercisable and expire five and one-half years from the date of issuance.

Rodman and Renshaw LLC served as the exclusive placement agent for the private placement.

At closing, the Company received proceeds of approximately $4.0 million after payment to the placement agent of an 8% cash fee and reimbursement of certain fees and expenses of the placement agent, in each case, pursuant to an engagement letter entered into with the placement agent on August 29, 2025. In addition, pursuant to such engagement letter, the Company issued to the placement agent (or its designees) warrants (“Placement Agent Warrants” and together with the Series F Warrants, the “common warrants”) to purchase up to an aggregate of 180,000 shares of common stock on the same terms as the Series F Warrants, except that the exercise price per share is 125% of the combined price per share and Series F Warrants sold in the offering.

Pursuant to the terms of the registration rights agreement, the Company has agreed to register for resale, at the Company’s expense, the 175,000 shares of common stock sold in the private placement and the 6,755,000 shares of common stock collectively exercisable pursuant to the Pre-Funded Warrants, the Series F Warrants and the Placement Agent Warrants. The Company has agreed to (i) file such a resale registration statement by October 24, 2025, (ii) use its best efforts to cause such registration statement to be declared effective by the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), as promptly as possible after filing (and in no event later than certain dates specified in the registration rights agreement, depending on the circumstances), and (iii) use its best efforts to keep such resale registration statement continuously effective under the Securities Act until the date that all shares of common stock registered thereunder have been sold or may be sold without registration under Rule 144. Failure by the Company to meet the filing deadlines and other requirements set forth in the registration rights agreement would subject the Company to certain specified liquidated damages amounts payable to the purchasers in the private placement.

Pursuant to the terms of the purchase agreement, the Company generally may not, until the date that is 90 calendar days after the date that the resale registration statement has been declared effective by the SEC, issue or enter into agreements to issue shares of common stock or securities convertible into or exercisable for common stock. In addition, the purchase agreement provides that until the date that is one year following the date that the resale registration statement is declared effective by the SEC, the Company may not, without the prior written consent of investors who purchased a majority of the securities sold in the private placement, (i) engage in certain “variable rate transactions” (as defined in the purchase agreement) related to its securities, or (ii) undertake a reverse or forward stock split or recapitalization, other than in the good faith determination of the Company’s board of directors to maintain its listing on the Nasdaq Capital Market.

Holders of the warrants will not have the right to exercise any portion of such warrants if such holder, together with its affiliates, would beneficially own in excess of 4.99% or 9.99% (at the initial election of the holder) of the number of shares of the Company’s common stock outstanding immediately after giving effect to such exercise, provided that a holder may increase or decrease such beneficial ownership limitation up to, and no higher than, 9.99%, by giving 61 calendar days’ notice to the Company.

1

The common warrants include certain rights upon a “fundamental transaction” (as defined in the common warrants), including the right of the holders thereof to receive from the Company or a successor entity cash or the same type or form of consideration (and in the same proportion) that is being offered and paid to the holders of common stock in such fundamental transaction in the amount of the “Black Scholes value” (as defined in such common warrants) of the unexercised portion of the applicable warrants on the date of the consummation of such fundamental transaction.

The shares of common stock and warrants sold and issued in the private placement were sold and issued without registration under the Securities Act in reliance on the exemptions provided by Section 4(a)(2) of the Securities Act as transactions not involving a public offering and Rule 506 promulgated under the Securities Act as sales to accredited investors.

The foregoing descriptions of the Pre-Funded Warrants, the Series F Warrants, the Placement Agent Warrants, the purchase agreement, and the registration rights agreement are not complete and are qualified in their entirety by reference to the full text of such warrants and/or agreements, the forms of which are attached hereto as Exhibits 4.1, 4.2, 4.3, 10.1 and 10.2, respectively, and are incorporated by reference into this Item 1.01.

Item 3.02. Unregistered Sales of Equity Securities.

The disclosures in Item 1.01 of this Current Report on Form 8-K are incorporated by reference into this Item 3.02.

Item 8.01. Other Events.

On October 9, 2025, the Company issued a press release announcing the pricing of the private placement, and on October 10, 2025, the Company issued a press release announcing the closing of the private placement. A copy of such press releases are attached hereto as Exhibits 99.1 and 99.2, respectively, and are incorporated by reference into this Item 8.01.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit		Description
4.1		Form of Pre-Funded Warrant.
4.2		Form of Series F Warrant.
4.3		Form of Placement Agent Warrant.
10.1		Form of Securities Purchase Agreement.
10.2		Form of Registration Rights Agreement.
99.1		Pricing Press Release, dated October 9, 2025.
99.2		Closing Press Release, dated October 10, 2025.
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	Bluejay Diagnostics, Inc.
	By:	/s/ Neil Dey
		Neil Dey
		President and Chief Executive Officer

Date: October 14, 2025

3